Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990040 · ClinicalTrials.gov registry record
Registry for Participants With Short Bowel Syndrome
A clinical trial of Short Bowel Syndrome, sponsored by Shire.
- Active
- Registry status
- 1,806
- Enrollment target
- 1
- Study location
NCT01990040 is a study of Short Bowel Syndrome that is active but no longer recruiting, run by Shire. The registered enrollment target is 1,806 participants, above the 79-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (2186% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01990040, a study of Short Bowel Syndrome, is active but no longer recruiting, sponsored by Shire.
- ACTIVE NOT RECRUITING
- Registry status
- 1,806 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
Conditions Studied
Study Locations (1)
Massachusetts
- Shire - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,806 participants |
| Start Date | 2014-06-23 |
| Est. Completion | 2032-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01990040
The ClinicalTrials.gov registry entry for NCT01990040 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,806 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 79-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (2186% higher). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01990040 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01990040 about?
NCT01990040 is a clinical study titled "Registry for Participants With Short Bowel Syndrome". This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants...
What is the current status of trial NCT01990040?
This trial is currently active not recruiting. The enrollment target is 1,806 participants. The study started on 2014-06-23. Estimated completion is 2032-06-30.
What conditions does trial NCT01990040 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
Who is sponsoring clinical trial NCT01990040?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01990040 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
RECRUITING · NA
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.